Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Inovio Pharmaceuticals (NYSEMKT:INO), Johnson & Johnson (NYSE:JNJ)

Pfizer Inc. (NYSE:PFE) announced encouraging top-line data from a phase IIIb study evaluating Genotropin for increasing height in small-for-gestational-age (SGA) children aged between 24 and 30 months. Pfizer Inc. (NYSE:PFE) stock performance was -0.25% in last session and finished the day at $32.10. Traded volume was 27.74million shares in the last session and the average volume of the stock remained 26.63million shares. The beta of … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Inovio Pharmaceuticals (NYSEMKT:INO), Johnson & Johnson (NYSE:JNJ)

Bullish Stocks: GTT Communications (NYSEMKT:GTT), MEI Pharma (NASDAQ:MEIP), Inovio Pharmaceuticals Inc. (NYSEMKT:INO), CONN’S (NASDAQ:CONN)

On March 18, 2014, GTT Communications, Inc. (NYSEMKT:GTT) issued a press release relating to the fourth quarter and year ended December 31, 2013 financial results. GTT Communications Inc. (NYSEMKT:GTT) stock performance was 11.86% in last session and finished the day at $10.85. Traded volume was 120,166.00 shares in the last session and the average volume of the stock remained 112,980.00 shares. The beta of the … Continue reading Bullish Stocks: GTT Communications (NYSEMKT:GTT), MEI Pharma (NASDAQ:MEIP), Inovio Pharmaceuticals Inc. (NYSEMKT:INO), CONN’S (NASDAQ:CONN)

Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Earlier this week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer’s (PFE – Analyst Report) Xalkori (crizotinib). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the … Continue reading Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Biotech Losers: Inovio Pharmaceuticals (NYSEMKT:INO), Oncomed Pharmaceuticals (NASDAQ:OMED), Enzymotec (NASDAQ:ENZY), Veracyte Inc (NASDAQ:VCYT)

Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) announced financial results for the quarter and year ended December 31, 2013. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. Traded volume was 10,401,414 million shares in the last session and the average volume of the stock remained 7.79 million shares. The beta of the stock remained 3.69. Inovio Pharmaceuticals Inc (NYSEMKT:INO) … Continue reading Biotech Losers: Inovio Pharmaceuticals (NYSEMKT:INO), Oncomed Pharmaceuticals (NASDAQ:OMED), Enzymotec (NASDAQ:ENZY), Veracyte Inc (NASDAQ:VCYT)

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)